According to Chinaventure, Junshi Biosciences has applied for the listing on the Sci-Tech innovation board. The company plans to raise 2.7 billion yuan with CICC as the lead underwriter, Guotai Junan Securities and Haitong Securities as the co-underwriters.
Junshi Biosciences is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and the clinical research and commercialization on a global scale. Its mission is to provide patients with treatment options that work better and cost less.
Based on the core platform technology of protein engineering, Junshi Biosciences stands at the frontier of R&D of macromolecular drugs. With distinguished capability of innovative drug discovery, advanced biotechnological R&D, large-scale production capacity, Junshi Biosciences has a leading edge in the PRC of immuno-oncology and the treatment of autoimmune and metabolic diseases.
Junshi Biosciences is the first PRC company to obtain NDA approval from the NMPA for the anti-PD-1 monoclonal antibody and to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody.
With the enrichment of product pipelines and exploration of drug combination therapies, Junshi Biosciences has developed more types of drugs, including small molecule drugs and antibody-drug conjugates (or ADCs), as well as to the exploration of the next-generation innovative therapies for cancer and autoimmune diseases.
China International Capital Corporation Limited (CICC) (3908.HK) is China’s first joint-venture investment bank. Since CICC's inception in 1995, it has been consistently committed to providing high-quality, value-added financial services to its clients. The company has established a full-service business model offering investment banking, equities, FICC, wealth management, and investment management.
GTJA, a comprehensive financial provider with a leading position in the Chinese securities industry, is always client-oriented and firmly based in the Chinese market to provide various financial services for individuals and institutional clients. Since 2008, GTJA has been rated as A level of AA class for nine consecutive years by CSRC, which is the highest rating for Chinese securities companies so far.